Heart HealthTwo Diabetes Drug Classes Show Promise After Pacemaker Implantation
Two widely used diabetes drug classes may improve outcomes after pacemaker implantation, but this study cannot prove they caused the benefits. Researchers analyzed records from 3,609 patients with type 2 diabetes who received pacemakers. Patients taking both an SGLT2 inhibitor and a GLP-1 receptor agonist had a 59% lower hazard of death and a 65% lower hazard of hospitalization for heart failure than patients taking neither. Either drug class alone was also associated with lower mortality, while results for heart failure hospitalization were less clear. These findings support randomized trials, not automatic treatment changes. Patients should discuss whether these medications fit their existing diabetes and heart care needs. The summary is based only on the abstract, which does not provide detailed safety findings or absolute event rates for each treatment group.
